TNFSF10 and hepatocellular carcinoma: Recently, low dose cisplatin was able to increase the expression of TRAIL agonistic receptor DR4/5, and enhanced the efficacy of MSC-TRAIL, eventually decreasing tumour growth in glioblastoma multiforme [177] and hepatocellular carcinoma animal models [178].